Even though the U.S. Supreme Court made a landmark ruling just under five months ago that pharmaceutical plaintiffs can’t sue generic drugmakers over drug warnings, plaintiffs lawyers are pushing for a number of theories that they say could provide recovery for their clients who took generic versions of drugs.

In the aftermath of Pliva Inc. v. Mensing, decided in June, 21 courts have dismissed claims over generic drugs, three courts have sustained some of plaintiffs’ claims and dismissed others, and two courts have sustained plaintiffs’ claims at the preliminary objection or summary judgment stage, according to a tally compiled by Drug and Device Law, a blog written by Dechert pharmaceutical defense attorneys.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]